



UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

09/634,352 08/09/00 CAO Y 03848-00029

HM12/0710

JOHN P. IWANICKI
BANNER & WITCOFF LTD
28TH FLOOR
28 STATE STREET
BOSTON MA 02109

EXAMINER

SIEW, J

ART UNIT

PAPER NUMBER

1656

DATE MAILED:

07/10/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Office Action Summary	Application No.		Applicant(s)	
	09/634,352		CAO ET AL.	
	Examiner		Art Unit	
	Jeffrey Siew		1656	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 09 August 2000.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-46 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-46 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Claim Objections

1. The numbering of claims is not in accordance with 37 CFR 1.126 which requires the original numbering of the claims to be preserved throughout the prosecution. When claims are canceled, the remaining claims must not be renumbered. When new claims are presented, they must be numbered consecutively beginning with the number next following the highest numbered claims previously presented (whether entered or not).

Misnumbered claims 42-45 been renumbered 43-46.

Claim Rejections - 35 USC § 112

2. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 20- 23 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

- A) In claim 23 the term "complete" is confusing. It cannot be determined how the term complete is measured i.e. complete set of genes, complete permutations of sequence etc.

Art Unit: 1656

B) Claims 20-22 indefinite because the two fold expression level is a result derived from method steps or type of samples. It is unclear as to the active step or limitation that would lead to such a result.

C) In claim 25 amplified nucleic acids lacks antecedent basis. It is unclear as to what amplified nucleic acids are being referred to.

Claim Rejections - 35 USC § 102

3. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

Claims 1-3,5,9,14,18, 29-33,35-37,39 & 43 are rejected under 35 U.S.C. 102(e) as being anticipated by Friend et al (US6,203,987 March 20, 2001).

Friend et al teach gene expression monitoring using an array and classification (see whole doc. esp. abstract). They teach the basic principles of gene expression monitoring using the hybridization patterns on a microarray (see col. 1 line 16-50). They examine the cellular state of a plurality of cells or a single cell (see col. 1 line 64 and col. 23 line 29). The sample may be a cell, tissue, organ or multicellular organism (see col. 5 line 34). The mRNA transcripts of cell are

Art Unit: 1656

examined by reverse transcription to DNA and bound to probes on a microarray (see col. 22 line 16-25). The probes may be between 50bp -2000bp. (see col. 24 line 35). They bind them to solid support such as glass, plastic (see col. 25 line4). The cDNA may labeled many of the well known and commonly practiced methods e.g. incorporations of fluorescently labeled dNTP or after synthesis they be labeled subsequently. A two color fluorescence labeling may be used to define alterations in the gene expression which allows the direct and internally controlled comparison of the mRNA levels corresponding to each arrayed gene in two cell states or to variations due to minor differences in experimental conditions (see col. 23 line17-32). They examine over 1000 genes (see col. 3 line 59). The hybridization the polynucleotides are perfectly matched (see col. 27 line 2). The method also has diagnostic purposes in examining tumors (see col. 18 line 64). They use a computer and software with a geneset database to classify the expression profile(see col. 20 line 20).

Claim Rejections - 35 USC § 103

4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various

Art Unit: 1656

claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 12,15-17,19-22,24,27,28,34 are rejected under 35 U.S.C. 103(a) as being unpatentable over Friend et al (US6,203,987 March 20, 2001) in view of Lockhart et al (Nature Biotechnology Vol. 14 pp. 1675-1660 Dec. 1996).

The teachings of Friend et al are described previously.

Friend et al do not mismatch probes, 10,000 genes and array density.

Lockhart et al teach expression monitoring by hybridization to high density oligonucleotide arrays (see whole doc. esp. abstract). They teach that high density containing 400,000 probes per area of 1.6cm^2 . They teach 25mer probes. The array may cover 40,000 human genes (see page 1679). They teach signal intensity is linearly related to target concentration between 1:300,000 and 1:3000 (see Figure 3). They teach the use of ESTs on the probes.

One of ordinary skill in the art would have been motivated to apply Lockhart et al's method of expression monitoring to Friend et al in order to quantitatively and simultaneous monitor the genes in the human body. Lockhart et al's high density arrays would allow direct monitoring of large numbers of mRNAs in parallel (see abstract). It would have been prima facie obvious to apply Lockhart et al's array to Friend et al's method of expression monitoring and classification in order to classify the many different genes in the human body simultaneously.

5. Claims 4,7,8,10,11,13 & 41 are rejected under 35 U.S.C. 103(a) as being unpatentable over Friend et al (US6,203,987 March 20, 2001) in view of Hampson et al (US6,066,457 May 23, 2000).

The teachings of Friend et al are described previously.

Friend et al do not teach transcripts of 500 base pair length.

Hampson et al teach creating cDNA of majority length of 100-500 base pairs (see whole doc. esp. col. 2 line 63).

One of ordinary skill in the art would have been motivated to apply Hampson et al's short transcripts to Friend et al's method of expression monitoring in order study differential gene expression. Hampson et al states that the short transcripts suitable for achieving uniform global PCR amplification representative of the original single stranded nucleic acid while maintaining correct strand sense. It would have been prima facie obvious to apply Hampson et al's method of producing short cDNA molecules to Friend et al's differential expression in order to obtain a representative sample of original mRNAs for accurate gene expression.

6. Claim 6 is rejected under 35 U.S.C. 103(a) as being unpatentable over Friend et al (US6,203,987 March 20, 2001) in view of Van Ness et al (6,248,521 June 19, 2001).

The teachings of Friend et al are described previously.

Friend et al do not teach incomplete extension by incorporation of ddNTP.

Van Ness et al teach that Tag based differential display allows amplification of partial cDNA sequences from subsets of mRNA from RT and PCR. This method allows direct comparison of two different cell types of samples (see whole doc. esp. col. 166 lines 18-33). They also teach ddNTP in primer extension reactions (see col. 17 line 1).

One of ordinary skill would have been motivated to employ ddNTPs in Van Ness method of differential display to Friend et al's array in order to compare different cell states. As ddNTP were well known chain terminators and would be expected to terminate the extension products with an expected high degree of success, it would have been prima facie obvious to apply Van Ness et al's partial cDNA sequences to Friend et al's array in order to directly compare the expression of different cell types.

7. Claims 23,45 & 46 are rejected under 35 U.S.C. 103(a) as being unpatentable over Friend et al (US6,203,987 March 20, 2001) in view of Hampson et al (US6,066,457 May 23, 2000) in further view of North et al (6,114,502 Sept. 5, 2000).

The teachings and suggestions of Friend et al and Hampson et al are described previously.

Friend et al do not teach studying neuron type cells nor complete array.

North et al teach the study of genes that express proteins in the retinal and brain that are associated with neurosensory defect (see whole doc. esp. abstract). They also teach complete array to study the hybridization.(see col. 12 line 34-53).

One of ordinary skill in the art would have been motivated to apply North et al nucleic acid compositions to Friend et al's gene expression monitoring in order to examine the TULP expression in relationship to retinal dystrophies. As the expression was correlated with neurosensory defect, it would have been prima facie obvious to study the expression of North et al's TULP sequences in the Friend et al's array in order to identify the cells that express the sequences for diagnostic and therapeutic purposes.

8. Claims 38,40 & 42 are rejected under 35 U.S.C. 103(a) as being unpatentable over Friend et al (US6,203,987 March 20, 2001) in view of Dale (US6,087,112 July 12, 2000).

The teachings of Friend et al are described previously.

Friend et al do not teach cell differentiation.

Dale et al teach array hybridization differentiation (see col. 6 line 37).

One of ordinary skill in the art would have been motivated to apply Dale et al's teaching of cell differentiation to Friend et al's method of gene expression monitoring in order to identify the gene expression and gene to gene relationship during the biological process. It would have been prima facie obvious to study cell differentiation as taught by Dale to Friend et al's arrays in order to identify the expressed genes during differentiation or apoptosis.

9. Claim 44 is rejected under 35 U.S.C. 103(a) as being unpatentable over Friend et al (US6,203,987 March 20, 2001) in view of Hampson et al (US6,066,457 May 23, 2000) and North et al (6,114,502 Sept. 5, 2000).in further view of Dale (US6,087,112 July 12, 2000).

The teachings and suggestions of Friend et al and Hampson et al and North are described previously.

Friend et al do not teach studying neuron type of adult brain and differentiation.

Dale et al teach array hybridization differentiation (see col. 6 line 37).

One of ordinary skill in the art would have been motivated to apply Dale et al's teaching of cell differentiation to Friend et al's method of gene expression monitoring in order to identify the gene expression and gene to gene relationship during the biological process. It would have been prima facie obvious to study cell differentiation as taught by Dale to Friend et al's arrays in order to identify the expressed genes during differentiation as related to neuronal expression of TULP proteins as they were involved in many defects as taught by North et al..

10. Claims 25 & 26 are rejected under 35 U.S.C. 103(a) as being unpatentable over Friend et al (US6,203,987 March 20, 2001) in view of Scanlon (US5,814,489 Sept. 29, 1998).

The teachings of Friend et al are described previously.

Friend et al do not teach incomplete extension by cleavage and end labeling.

Scanlon et al teach cleavage of amplification of mRNA and end labeling(see whole doc. esp. col. 4 lines 29-46)

One of ordinary skill in the art would have been motivated to cleave the amplification products of Friend et al and end label in order to detect changes in gene expression at the messenger level. As it was well known and commonly practiced in the art to end label fragment for detection it would have been prima facie obvious to amplify, cleave and end label fragments

Art Unit: 1656

in Friend et al's assay in order to detect and identify specific mRNAs for gene expression monitoring.

SUMMARY

11. No claims allowed.

CONCLUSION

12. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jeffrey Siew whose telephone number is (703) 305-3886 and whose e-mail address is Jeffrey.Siew@uspto.gov. However, the office cannot guarantee security through the e-mail system nor should official papers be transmitted through this route. The examiner can best be reached on Monday through Thursday from 6:30 a.m. to 4 p.m. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Jones, can be reached on (703)-308-1152.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist for Technology Center 1600 whose telephone number is (703) 308-0196.

Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official

Application/Control Number: 09/634,352

Page 11

Art Unit: 1656

Gazette, 1096 OG 30 (November 15, 1989). The CM1 Center numbers for Group 1600 are Voice (703) 308-3290 and Fax (703) 308-4556 or (703) 308-4242.



Jeffrey Siew

July 9, 2001